SLCO1B1 and myopathy: Statins, or 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, are cholesterol-lowering medications used by millions of patients for the primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD).6 In 2008, a genome-wide association study7 identified an association between the common nonsynonymous c.521T>C variant in SLCO1B1 (rs4149056) and severe simvastatin-related myopathy, and subsequent studies8,9,10 have reported an association between this variant and milder phenotypes of statin intolerance.